Evolving trends in dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP): a 4-year cohort analysis.

The mean number of surgeries also exhibited a decreasing trend as shown in Fig. 1 A, although not significant from 3.0 ± 3.9 in 2019/20 to 2.3 ± 1,25 in 2023, alongside variability in the average years since the last ESS, which ranged from 4.4 ± 4.8 years in 2019/20 to 6.5 ± 7.2 years in 2023.

also in 28,420 other papers

While variation was minor, a modest dip in 2021 and 2022 suggests a possible trend toward earlier initiation of biologic therapy.

also in 888 other papers